The purpose of Core B is to provide a Program for Pilot/Feasibility Studies in association with the HCV Persistence Study Group (HPSG). Core B will be located in Dr. Chung's laboratory/office complex at the Liver Center/Gastrointestinal Division of Massachusetts General Hospital. The main goals of Core B are to administer and oversee the Pilot/Feasibility Studies Program of the HPSG. The specific tasks of Core B will be to: (a) solicit applications for the PES program annually;(b) provide a mechanism for scientific peer review of the PES applications;(c) monitor research progress;and (d) to organize an annual scientific symposium (in conjunction with the annual visit of the U19 External Scientific Advisory Group) for PES awardees to present their research findings;In this regard. Core B will be closely intertwined with the operations of Core A (Administrative), as there will be substantive thematic overlap between the two cores. It is expected that one of the key benefits of Core B's activities will be to foster additional scientific interactions between members of the local scientific community and the PIs of the HPSG program.

Public Health Relevance

CORE B is an essential structure that will support pilot and feasibility projects that enhance and enrich the scope and quality ofthe science ofthe main Projects and Cores ofthe Hepatitis C Persistence Study Group, in so doing fostering new interactions with HPSG Pis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI082630-06
Application #
8726066
Study Section
Special Emphasis Panel (ZAI1-LAR-I (J1))
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
6
Fiscal Year
2014
Total Cost
$69,290
Indirect Cost
$19,290
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Lin, Wenyu; Zhu, Chuanlong; Hong, Jian et al. (2015) The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. J Hepatol 62:1024-32
Jilg, Nikolaus; Lin, Wenyu; Hong, Jian et al. (2014) Kinetic differences in the induction of interferon stimulated genes by interferon-* and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59:1250-61
Kroy, Daniela C; Ciuffreda, Donatella; Cooperrider, Jennifer H et al. (2014) Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146:550-61
Lee, Mark N; Ye, Chun; Villani, Alexandra-ChloƩ et al. (2014) Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 343:1246980
Crawford, Alison; Angelosanto, Jill M; Kao, Charlly et al. (2014) Molecular and transcriptional basis of CD4? T cell dysfunction during chronic infection. Immunity 40:289-302
Feeney, Eoin R; Chung, Raymond T (2014) Antiviral treatment of hepatitis C. BMJ 348:g3308
Fackler, Oliver T; Murooka, Thomas T; Imle, Andrea et al. (2014) Adding new dimensions: towards an integrative understanding of HIV-1 spread. Nat Rev Microbiol 12:563-74
Xiao, Yanping; Yu, Sanhong; Zhu, Baogong et al. (2014) RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 211:943-59
Veerapu, Naga Suresh; Park, Su-Hyung; Tully, Damien C et al. (2014) Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 124:3469-78
Ussher, James E; Bilton, Matthew; Attwod, Emma et al. (2014) CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol 44:195-203

Showing the most recent 10 out of 72 publications